Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Nutlin-3a + Paclitaxel|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Nutlin-3a||Nutlin|Nutlin-3||MDM2 Inhibitor 19||Nutlin-3a is an MDM2 inhibitor which activates p53 and results in cancer cells undergoing apoptosis and cellular senescence. Nutlin-3 is a candidate for neoadjuvant therapy in cancers with a functional p53 (PMID: 18451145, PMID: 32653500).|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 12 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||Nutlin-3a + Paclitaxel||Preclinical - Cell culture||Actionable||In a preclinical study, the combination of Nutlin-3 and Taxol (paclitaxel) resulted in a synergistic effect and inhibited the growth of triple-receptor negative breast cancer cells in culture (PMID: 27872098).||27872098|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|